The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

Hidradenitis suppurativa is more common among patients with Crohn disease (CD) than ulcerative colitis (UC), yet bowel obstruction affects both CD and UC.

CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company with a market capitalization of ...

Financial Highlights for the Second Quarter of Fiscal 2025 Biomerica continued to deliver improved financial performance, demonstrating revenue growth, disciplined cost management, and progress toward ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in ...

Nitroimidazole derivatives are the drugs of choice for treatment of amoebic colitis, as they are very ... limit their use and are now rarely used. Aspiration of the abscess might be necessary ...

Year - Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) ...

Vitamin D is an essential vitamin that may interact with other medications and supplements, such as statins, thiazide ...

More than half of Coloradans have reported being worried about the costs of prescription medications they and their families ...